环泊酚对老年腰椎手术患者麻醉诱导期循环影响研究

注册号:

Registration number:

ChiCTR2300069858 

最近更新日期:

Date of Last Refreshed on:

2023-08-11 23:05:19 

注册时间:

Date of Registration:

2023-03-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

环泊酚对老年腰椎手术患者麻醉诱导期循环影响研究

Public title:

Study on the effect of cyclophenol on circulation in elderly patients undergoing lumbar surgery during anesthesia induction

注册题目简写:

环泊酚对老年腰椎手术患者麻醉诱导期循环影响研究

English Acronym:

Study on the effect of cyclophenol on circulation in elderly patients undergoing lumbar surgery during anesthesia induction

研究课题的正式科学名称:

环泊酚对老年腰椎手术患者麻醉诱导期循环影响研究

Scientific title:

Study on the effect of cyclophenol on circulation in elderly patients undergoing lumbar surgery during anesthesia induction

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

姚罡 

研究负责人:

姚罡 

Applicant:

Yao Gang 

Study leader:

Yao Gang 

申请注册联系人电话:

Applicant telephone:

+86 152 7708 0060

研究负责人电话:

Study leader's
telephone:

+86 152 7708 0060

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1789834686@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1789834686@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广西柳州市柳南区龙屯路4号

研究负责人通讯地址:

广西柳州市柳南区龙屯路4号

Applicant address:

4 Longtun Road, Liunan District, Liuzhou, Guangxi

Study leader's address:

4 Longtun Road, Liunan District, Liuzhou, Guangxi

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

柳州市工人医院

Applicant's institution:

Liuzhou Workers' Hospital

研究负责人所在单位:

柳州市工人医院

Affiliation of the Leader:

Liuzhou Workers' Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY2023404

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

柳州市工人医院伦理委员会

Name of the ethic committee:

Ethics Committee of Liuzhou Workers' Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-03-07 00:00:00

伦理委员会联系人:

周丽华

Contact Name of the ethic committee:

Zhou Lihua

伦理委员会联系地址:

广西柳州市和平路156号

Contact Address of the ethic committee:

156 Liushi Road, Liuzhou, Guangxi

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

柳州市工人医院

Primary sponsor:

Liuzhou Workers' Hospital

研究实施负责(组长)单位地址:

广西柳州市和平路156号

Primary sponsor's address:

156, Heping Road, Liuzhou, Guangxi

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中华人民共和国

省(直辖市):

广西壮族自治区

市(区县):

柳州

Country:

China

Province:

the Guangxi Zhuang Autonomous Region

City:

Liuzhou

单位(医院):

柳州市工人医院

具体地址:

广西柳州市和平路156号

Institution
hospital:

Liuzhou Workers' Hospita

Address:

156, Heping Road, Liuzhou, Guangxi

经费或物资来源:

自筹

Source(s) of funding:

Self-financing

研究疾病:

老年腰椎疾病  

Target disease:

Lumbar diseases in the elderly

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

分析两组不同麻醉药物对老年腰椎手术患者安全性、有效性及循环稳定性的影响,为降低围术期术老年患者循环波动及不良事件的发生,为改善患者预后提供临床参考。  

Objectives of Study:

To analyze the effects of two groups of different anesthetic drugs on the safety, effectiveness and circulation stability of elderly patients undergoing lumbar surgery, in order to reduce the occurrence of circulation fluctuations and adverse events in elderly patients undergoing perioperative surgery, and to provide clinical reference for improving the prognosis of patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.术前存在精神或意识障碍者; 2.长期服用镇静药物患者; 3.超重或肥胖者(体重指数>=28); 4.对本研究相关麻醉药物有用药禁忌证者; 5.术前合并严重肝肾功能损害者。

Exclusion criteria:

1. Patients with preoperative mental or consciousness disorders; 2. Patients who take sedative drugs for a long time; 3. Overweight or obese individuals (body mass index>=28); 4. Those who have contraindications to the use of anesthetic drugs related to this study; 5. Patients with severe liver and kidney function damage before surgery.

研究实施时间:

Study execute time:

From 2023-04-01 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-04-01 00:00:00 To 2023-04-01 00:00:00

干预措施:

Interventions:

组别:

环泊酚组

样本量:

30

Group:

Cyclophenol group

Sample size:

干预措施:

麻醉诱导使用环泊酚(0.4mg/kg)

干预措施代码:

Intervention:

Cyclopol group anesthesia induction (0.4mg/kg )

Intervention code:

组别:

丙泊酚组

样本量:

30

Group:

Propofol group

Sample size:

干预措施:

麻醉诱导使用丙泊酚(2mg/kg)

干预措施代码:

Intervention:

Anesthesia induction with propofol (2mg/kg)

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中华人民共和国

省(直辖市):

广西 

市(区县):

 

Country:

China

Province:

the Guangxi Zhuang Autonomous Region

City:

单位(医院):

柳州市工人医院 

单位级别:

三甲 

Institution
hospital:

Liuzhou Workers' Hospita

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

无创脑电双频指数监测

指标类型:

主要指标

Outcome:

BIS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心脏排血指数

指标类型:

主要指标

Outcome:

CI

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

动脉血压变异率

指标类型:

主要指标

Outcome:

PPV

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

T1-T0

指标类型:

主要指标

Outcome:

T1-T0

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

收缩压

指标类型:

次要指标

Outcome:

systolic pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

舒张压

指标类型:

次要指标

Outcome:

diastolic pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

平均动脉压

指标类型:

次要指标

Outcome:

mean arterial pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

去氧肾上腺素

指标类型:

次要指标

Outcome:

Deoxyepinephrine

Type:

Secondary indicator

测量时间点:

测量方法:

使用剂量

Measure time point of outcome:

Measure method:

Dose used

指标中文名:

阿托品

指标类型:

次要指标

Outcome:

atropine

Type:

Secondary indicator

测量时间点:

测量方法:

使用剂量

Measure time point of outcome:

Measure method:

Dose used

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用随机数字表法将 60 例患者分为试验组和对照组,把 60 个信封外面写上编号,信封内有对应的随机数字和麻醉诱导方案,严格保密和保管。在研究医院病房招募择期行心脏瓣膜置换术患者,术前1日按照纳入标准、排除标准确定受试者,按照签署知情同意书的顺序编号。手术当日取出相应序号信封获取麻醉诱导方案,并由另一名不知情麻醉方案的人进行观察和记录各项指标。所有数据锁定后,由统计人员进行分析,得出分析结果后进行揭盲。

Randomization Procedure (please state who generates the random number sequence and by what method):

60 patients were divided into test group and control group by random number table method. The 60 envelopes were numbered with corresponding random numbers and anesthesia induction scheme inside, which were strictly confidential and kept. The patients who were recruited for elective cardiac valve replacement in the&

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

在研究完成后随论文发表作为附件公开原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Raw data to be published as an annex to the paper upon completion of the study

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

研究人员采用纸质表格在病人床旁收集观察数据,后交由实验数据分析人员统一管理分析

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Observation data are collected at the patient's bedside using paper forms and then handed over to the experimental data analysts for centralised management and analysis

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-03-28 11:20:53